Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bio-Path Holdings (BPTH)

Bio-Path Holdings (BPTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,851
  • Shares Outstanding, K 679
  • Annual Sales, $ 0 K
  • Annual Income, $ -16,080 K
  • 60-Month Beta 0.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.27
Trade BPTH with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 127.15%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,407.96% on 02/13/24
  • IV Low 0.00% on 04/19/24
  • Put/Call Vol Ratio 0.17
  • Today's Volume 7
  • Volume Avg (30-Day) 177
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 1,240
  • Open Int (30-Day) 751

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -4.54
  • Number of Estimates 1
  • High Estimate -4.54
  • Low Estimate -4.54
  • Prior Year -13.20
  • Growth Rate Est. (year over year) +65.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +58.60%
on 04/16/24
7.67 -44.07%
on 04/18/24
-0.27 (-5.92%)
since 03/19/24
3-Month
2.70 +58.60%
on 04/16/24
9.99 -57.05%
on 02/08/24
-3.85 (-47.30%)
since 01/19/24
52-Week
2.70 +58.60%
on 04/16/24
44.80 -90.42%
on 06/23/23
-24.61 (-85.16%)
since 04/19/23

Most Recent Stories

More News
Bio-Path: Q3 Earnings Snapshot

Bio-Path: Q3 Earnings Snapshot

BPTH : 4.29 (+2.14%)
Bio-Path: Q2 Earnings Snapshot

Bio-Path: Q2 Earnings Snapshot

BPTH : 4.29 (+2.14%)
Bio-Path: Q1 Earnings Snapshot

Bio-Path: Q1 Earnings Snapshot

BPTH : 4.29 (+2.14%)
Bio-Path: Q3 Earnings Snapshot

Bio-Path: Q3 Earnings Snapshot

BPTH : 4.29 (+2.14%)
Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022

HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize®...

BPTH : 4.29 (+2.14%)
Bio-Path Holdings Reports First Quarter 2022 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET...

BPTH : 4.29 (+2.14%)
Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022

HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense...

BPTH : 4.29 (+2.14%)
Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

Preclinical Data Support BP1003 Combination Therapy to Treat Breast and Ovarian Cancers...

BPTH : 4.29 (+2.14%)
Bio-Path Holdings Reports Full Year 2021 Financial Results

Conference Call to be Held Today at 8:30 A.M. ET...

BPTH : 4.29 (+2.14%)
Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting

HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilizeâ„¢...

BPTH : 4.29 (+2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development. Bio-Path's drug delivery technology distributes nucleic acid drugs systemically, throughout...

See More

Key Turning Points

3rd Resistance Point 10.84
2nd Resistance Point 9.25
1st Resistance Point 6.73
Last Price 4.29
1st Support Level 2.62
2nd Support Level 1.03
3rd Support Level N/A

See More

52-Week High 44.80
Fibonacci 61.8% 28.72
Fibonacci 50% 23.75
Fibonacci 38.2% 18.79
Last Price 4.29
52-Week Low 2.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar